Drug Profile


Alternative Names: ZP 4207; ZP-GA-1

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator Zealand Pharma
  • Developer Beta Bionics; Boston University; Zealand Pharma
  • Class Antihypoglycaemics; Peptides
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypoglycaemia; Type 1 diabetes mellitus

Most Recent Events

  • 10 Jun 2017 Efficacy and adverse events data from a phase II trial in Type-1 diabetes mellitus presented at the 77th Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 23 May 2017 Efficacy and adverse events data from a phase IIa trial in Type-1 diabetes mellitus released by Zealand Pharma
  • 17 May 2017 The Committee of Orphan Medicinal Products recommends Orphan Drug Designation for Congenital hyperinsulinism in EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top